Hepion Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
HEPA$0.11-13.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Preferred StockSeries A · Preferred StockSeries C · Common Stock · AdditionalPaid inCapital · Accumulated Other Comprehensive Loss · AccumulatedDeficit · TotalStockholders'Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||
| Balance at December 31, 2021 | 85,581 | $855,808 | 1,806 | $845,320 | 3,811,263 | $381 | $224,794,789 | $— | $(133,501,295) | $92,995,003 |
| Adoption of new accounting standard | — | — | — | — | — | — | — | — | — | — |
| Net loss | — | — | — | — | — | — | — | — | (42,200,049) | (42,200,049) |
| Other comprehensive income/loss | — | — | — | — | — | — | — | (90,168) | — | (90,168) |
| Stock-based compensation expense | — | — | — | — | — | — | 2,283,643 | — | — | 2,283,643 |
| Deemed dividend related to Series F and Series G Convertible Redeemable Preferred Stock | — | — | — | — | — | — | (3,137,500) | — | — | (3,137,500) |
| Conversion of preferred stock to common | — | — | (5) | (5,000) | 2 | — | 5,000 | — | — | — |
| Issuance of common stock, net | — | — | — | — | 216 | — | 5,008 | — | — | 5,008 |
| Balance at December 31, 2022 | 85,581 | 855,808 | 1,801 | 840,320 | 3,811,481 | 381 | 223,950,940 | (90,168) | (175,701,344) | 49,855,937 |
| Net loss | — | — | — | — | — | — | — | — | (48,926,042) | (48,926,042) |
| Other comprehensive loss | — | — | — | — | — | — | — | 11,389 | — | 11,389 |
| Stock-based compensation expense | — | — | — | — | — | — | 1,340,311 | — | — | 1,340,311 |
| Stock-based liability awards converted to equity | — | — | — | — | — | — | 2,983,006 | — | — | 2,983,006 |
| Issuance of common stock in connection with stock split | — | — | — | — | 26,807 | 3 | (3) | — | — | — |
| Conversion of preferred stock to common | — | — | (113) | (1,000) | 52 | — | 1,000 | — | — | — |
| Issuance of common stock, net | — | — | — | — | 400,000 | 40 | — | — | — | 40 |
| Warrant exercises | — | — | — | — | 580,393 | 58 | 2,016,108 | — | — | 2,016,166 |
| Balance at December 31, 2023 | 85,581 | $855,808 | 1,688 | $839,320 | 4,818,733 | $482 | $230,291,362 | $(78,779) | $(224,627,386) | $7,280,807 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.